Dexpramipexole
Dexpramipexole is a small molecule pharmaceutical. It is currently being investigated in clinical studies.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
No data
Clinical
Clinical Trials
167 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Parkinson disease | D010300 | EFO_0002508 | G20 | 2 | 10 | 21 | 17 | 26 | 74 |
| Restless legs syndrome | D012148 | EFO_0004270 | G25.81 | — | 4 | 7 | 11 | 7 | 28 |
| Healthy volunteers/patients | — | — | — | 11 | — | — | 1 | 1 | 13 |
| Depression | D003863 | — | F33.9 | — | 1 | 2 | 5 | 2 | 10 |
| Bipolar disorder | D001714 | EFO_0000289 | F30.9 | — | 3 | — | 2 | — | 5 |
| Major depressive disorder | D003865 | EFO_0003761 | F22 | — | 1 | 1 | 1 | — | 3 |
| Sleep wake disorders | D012893 | — | G47 | — | 1 | 1 | 1 | — | 2 |
| Treatment-resistant depressive disorder | D061218 | — | — | — | — | — | 1 | 1 | 2 |
| Stroke | D020521 | EFO_0000712 | I63.9 | — | — | — | 1 | — | 1 |
| Brain neoplasms | D001932 | EFO_0003833 | C71 | — | — | — | 1 | — | 1 |
Show 7 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Amyotrophic lateral sclerosis | D000690 | HP_0007354 | G12.21 | 7 | 4 | 2 | — | 1 | 12 |
| Asthma | D001249 | EFO_0000270 | J45 | — | 1 | 3 | — | — | 4 |
| Anhedonia | D059445 | — | R45.84 | — | 1 | 2 | — | — | 3 |
| Tourette syndrome | D005879 | EFO_0004895 | F95.2 | — | 1 | 1 | — | — | 2 |
| Eosinophilia | D004802 | HP_0001880 | D72.1 | — | 1 | 1 | — | — | 2 |
| Schizophrenia | D012559 | EFO_0000692 | F20 | — | — | 1 | — | — | 1 |
| Psychotic disorders | D011618 | — | F20.81 | — | — | 1 | — | — | 1 |
| Essential tremor | D020329 | EFO_0003108 | G25.0 | — | — | 1 | — | — | 1 |
| Opioid-related disorders | D009293 | EFO_0005611 | F11 | — | 1 | 1 | — | — | 1 |
| Post-traumatic stress disorders | D013313 | EFO_0001358 | F43.1 | — | — | 1 | — | — | 1 |
Show 2 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Central nervous system diseases | D002493 | HP_0002011 | G96.9 | — | 2 | — | — | — | 2 |
| Brain diseases | D001927 | HP_0001298 | G93.40 | — | 2 | — | — | — | 2 |
| Movement disorders | D009069 | HP_0100022 | — | — | 2 | — | — | — | 2 |
| Neurodegenerative diseases | D019636 | EFO_0005772 | G31.9 | — | 2 | — | — | — | 2 |
| Parkinsonian disorders | D020734 | HP_0001300 | G20.C | — | 1 | — | — | 1 | 2 |
| Obsessive-compulsive disorder | D009771 | EFO_0004242 | F42 | 1 | 1 | — | — | — | 2 |
| Anxiety | D001007 | EFO_0005230 | F41.1 | — | 1 | — | — | 1 | 2 |
| Fibromyalgia | D005356 | EFO_0005687 | M79.1 | — | 1 | — | — | — | 1 |
| Renal colic | D056844 | EFO_1001412 | N23 | 1 | 1 | — | — | — | 1 |
| Depressive disorder | D003866 | EFO_1002014 | F32.A | — | 1 | — | — | — | 1 |
Show 5 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Cocaine-related disorders | D019970 | — | F14 | 1 | — | — | — | — | 1 |
| Substance-related disorders | D019966 | EFO_0003890 | F13 | 1 | — | — | — | — | 1 |
| Chronic pain | D059350 | HP_0012532 | — | 1 | — | — | — | — | 1 |
| Renal insufficiency | D051437 | HP_0000083 | N19 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Multiple system atrophy | D019578 | — | — | — | — | — | — | 1 | 1 |
| Neurologic gait disorders | D020233 | HP_0003376 | R26.1 | — | — | — | — | 1 | 1 |
| Huntington disease | D006816 | Orphanet_399 | G10 | — | — | — | — | 1 | 1 |
| Progressive supranuclear palsy | D013494 | EFO_0002512 | G23.1 | — | — | — | — | 1 | 1 |
| Corticobasal degeneration | D000088282 | — | G31.85 | — | — | — | — | 1 | 1 |
| Emotions | D004644 | — | — | — | — | — | — | 1 | 1 |
| Motivation | D009042 | — | — | — | — | — | — | 1 | 1 |
| Reward | D012201 | — | — | — | — | — | — | 1 | 1 |
| Heart failure | D006333 | HP_0001635 | I50 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Dexpramipexole |
| INN | dexpramipexole |
| Description | Dexpramipexole is a first-in-class oral investigational medicine that lowers blood and tissue eosinophils before they can cause damage in the target organ. Dexpramipexole is being developed by Areteia Therapeutics and has the potential to be the first oral treatment ever approved for eosinophilic asthma.
|
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CCCN[C@@H]1CCc2nc(N)sc2C1 |
Identifiers
| PDB | — |
| CAS-ID | 104617-86-9 |
| RxCUI | — |
| ChEMBL ID | CHEMBL249420 |
| ChEBI ID | — |
| PubChem CID | 59868 |
| DrugBank | — |
| UNII ID | WI638GUS96 (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 389 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
0 adverse events reported
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use